Sanofi

Ataciguat, an oral soluble guanylate cyclase activator, demonstrated significant improvements in cardiac function and slowed aortic valve calcium progression in a Phase 2 trial of 23 patients with moderate calcific aortic valve stenosis.

Biomunex presents preclinical data on its MAIT engager platform at the 2025 SITC Annual Meeting, showcasing a new class of bispecific antibodies that target MAIT cells for cancer treatment.

Neok Bio launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.

Takeda's QDENGA dengue vaccine achieved 61.2% efficacy in preventing virologically confirmed dengue after 4.5 years in the pivotal Phase 3 TIDES trial.

Hemlibra has shown efficacy in preventing bleeding during exercise for patients with Hemophilia A, marking a significant advancement in activity-related bleeding management.

AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.

Sanofi and Medidata announced an expansion of their 10-plus-year collaboration to leverage AI-embedded platform solutions across clinical workflows.

Inhibrx Biosciences will host a webcast on October 23, 2025, to present topline results from the registrational ChonDRAgon study of ozekibart in advanced chondrosarcoma patients.

Electra Therapeutics' ELA026 becomes the first investigational therapy to receive both FDA Breakthrough Therapy designation and EMA Priority Medicines designation for secondary hemophagocytic lymphohistiocytosis (sHLH).

Sanofi's efdoralprin alfa demonstrated statistically significant superiority over standard plasma-derived therapy in the ElevAATe phase 2 study, meeting all primary and key secondary endpoints for alpha-1 antitrypsin deficiency emphysema treatment.